Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.

Saved in:
Bibliographic Details
Title: Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.
Authors: Schaefer IM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ischaefer@bwh.harvard.edu., Hemming ML; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA., Lundberg MZ; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Serrata MP; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Goldaracena I; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Liu N; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Yin P; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA., Paulo JA; Department of Cell Biology, Harvard Medical School, Boston, MA, USA., Gygi SP; Department of Cell Biology, Harvard Medical School, Boston, MA, USA., George S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA., Morgan JA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA., Bertagnolli MM; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Sicinska ET; Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chu C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Zheng S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA., Mariño-Enríquez A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Hornick JL; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA., Raut CP; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ou WB; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China., Demetri GD; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA., Saka SK; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.; European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany., Fletcher JA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Sarcoma Center, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Source: British journal of cancer [Br J Cancer] 2022 Nov; Vol. 127 (11), pp. 2072-2085. Date of Electronic Publication: 2022 Sep 29.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-1827
DOI:10.1038/s41416-022-01990-5